Sundrug Co.,Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sundrug Co.,Ltd.'s yearly results (2023–2026), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 92% of Healthcare companies in Japan.
- Debt Due Cover Ratio: Debt due within a year is covered 7.1 times by its yearly operating cash. Higher than 85% of Healthcare companies in Japan.
Where ¥100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥138Over the last 3 years, every ¥100 of reported profit came with ¥138 of operating cash.
Higher than 55% of Healthcare companies in Japan.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Lower than 54% of Healthcare companies in Japan.
Cash Locked Ratio
¥6For every ¥100 of sales, ¥6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥3 tied up three years earlier.
Less money tied up than 68% of Healthcare companies in Japan.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 92% of Healthcare companies in Japan.
Growth Efficiency Ratio
¥4Sales grew 22% in 3 years; of every extra ¥100 of sales, ¥4 became extra profit.
Lower than 53% of Healthcare companies in Japan.
Asset Productivity Ratio
+22% / +32%In 3 years sales changed by +22% while total assets changed by +32%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
7.1×Debt due within a year is covered 7.1 times by its yearly operating cash.
Higher than 85% of Healthcare companies in Japan.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Higher than 53% of Healthcare companies in Japan.
Tangible Assets Ratio
98%Of every ¥100 the company owns, ¥98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 61% of Healthcare companies in Japan.
Tangible Net Worth Ratio
97%Of every ¥100 of net worth, ¥97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 62% of Healthcare companies in Japan.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Sundrug Co.,Ltd. owes ¥0.40 for every ¥1 it owns. Net profit rose 2% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
13.5Investors pay ¥13.5 for every ¥1 of Sundrug Co.,Ltd.'s yearly profit, lower than 60% of Healthcare companies in Japan.
P/B ratio
1.45The share price is 1.45 times Sundrug Co.,Ltd.'s book value per share, lower than 54% of Healthcare companies in Japan.
Market cap
¥415.9 BThe total market value of all of Sundrug Co.,Ltd.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in Japan. PosiCap size class: Meso Cap.
Net worth (book value)
¥286.0 BWhat Sundrug Co.,Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
¥2,445Net worth divided by the number of shares. The share price of ¥3,555 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
11.3%Sundrug Co.,Ltd. earned 11.3% on its shareholders' money over the last year, higher than 71% of Healthcare companies in Japan.
Owes vs Owns
0.40×Sundrug Co.,Ltd. owes ¥0.40 for every ¥1 it owns (low), higher than 52% of Healthcare companies in Japan.
Dividend yield
3.65%Sundrug Co.,Ltd. pays 3.65% of its share price as dividends a year, higher than 76% of dividend-paying Healthcare companies in Japan.
Revenue growth
+5%Revenue rose 5% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit growth
+2%Net profit rose 2% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Profit margin
3.7%Sundrug Co.,Ltd. keeps ¥4 of every ¥100 of revenue as net profit.
Cash quality
1.4×Cash from Sundrug Co.,Ltd.'s business was 1.4× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
122.0×Sundrug Co.,Ltd.'s operating profit covered its interest costs 122.0 times in the year to Mar 2026.
Cash vs debt
Net cashSundrug Co.,Ltd. held ¥22.3 B more cash than debt (net cash) at Mar 2026.
Questions
What is Sundrug Co.,Ltd.'s P/E ratio?
Investors pay ¥13.5 for every ¥1 of Sundrug Co.,Ltd.'s yearly profit, lower than 60% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sundrug Co.,Ltd.: ¥415.9 B ÷ ¥286.0 B (31 Mar 2026) = 1.5.
What is Sundrug Co.,Ltd.'s return on equity?
Sundrug Co.,Ltd. earned 11.3% on its shareholders' money over the last year, higher than 71% of Healthcare companies in Japan.
How much does Sundrug Co.,Ltd. owe compared with what it owns?
Sundrug Co.,Ltd. owes ¥0.40 for every ¥1 it owns (low), higher than 52% of Healthcare companies in Japan.
Does Sundrug Co.,Ltd. pay a dividend?
Yes. Sundrug Co.,Ltd. pays 3.65% of its share price as dividends a year, higher than 76% of dividend-paying Healthcare companies in Japan.
Is Sundrug Co.,Ltd.'s revenue growing?
Revenue rose 5% in the year to Mar 2026, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.